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Fig.2 Ulcer of distal skin and blackening and gangrene of the 1st to the
4th toes in the right foot.
Fig.3 Contrast-enhanced X-ray manifestations: diffuse and continuous
pipestem or pipe-like calcification of middle and small arteries; marked ste-
nosis of part lumens. A large number of calcification foci could be found in
soft tissue around joints.
Fig.4 Multiple patchy and mass-like strong echoes adhering to the
capsule walls, with acoustic shadows accompanying behind, were found in
the cavities.
Fig.5 Calcium salt deposition and multinucleated giant cell aggregation
with granuloma reaction were found in pathological examination.
Fig.6 Near infrared spectrometer, composition: hydroxylapatite 70%,
proteins 20%, calcium oxalate monohydrate 10%.
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Successful Pregnancy and Labor for Women with Uremia: Report of 6
Cases with a Literature Review
Wei Shen, Qiang He, Yiwen Li
Kidney Disease Center, Zhejiang Provincial People’s Hospital, Hangzhou,
Zhejiang, China
Objective: The aim of this study was to summarize and analyze the clinical
manifestations for pregnant women with uremia.
Methods: Data on 6 pregnant female patients with uremia were retrospec-
tively analyzed with literature were reviewed.
Results: Five patients of pregnancy after renal transplantation were main-
tained on an immunosuppressive regimen before, during, and after the preg-
nancy, with none developing severe complication. Their offspring had
normal birth weight, postnatal growth and development. The function and
survival of renal allograft was not adversely affected by pregnancy. The
other one with uremia undergone hemodialysis experienced selective preg-
nancy terminated. Newborns delivered to the patient had low birth weight,
but no congenital defects were noted and development was normal.
Conclusion: The reasonable immunosuppressive regimen, prevention and
prompt therapy of complication, regular followed-up examination appears
to be crucial factors for a favourable pregnancy outcome for women with
uremia.http://dx.doi.org/10.1016/j.hkjn.2015.09.154
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Prevalence, Treatment, and Control of Hypertension in CKD Inpatients
of a Large Comprehensive Hospital in Eastern China: A Retrospective,
Single-center Survey
Zhang Wei, Liu Yueming, He Qiang
Department of Nephrology, Zhejiang Provincial People’s Hospital, China
Objective: This study aimed to assess the situation of prevalence, treatment
and control of hypertension in inpatients with chronic kidney disease.
Methods: This was a retrospective, single center study and cross-sectional
clinical epidemiology study.
Results: (1) 59.8% (438/733) inpatients were diagnosed with hypertension.
The average SBP of patients with hypertension was 142.03  20.98 mmHg
and 138.69  16.49 mmHg on admission and discharge, respectively
(p < 0.001). (2) 31.3% patients with hypertension were treated by one
type of antihypertensive drug, and this percentage was 36.5%, 22.8% and
9.6% in patients with two, three and four or more types of antihyperten-
sive drugs, respectively. 46.3% patients with hypertension used RASI.
CCB was used in 91.6% of patients with hypertension. (3) The percentage
of patients with BP < 140/90 mmHg was 49.3% on admission, and increased
to 53.2% when the patients were discharged (p < 0.001). On admission, the
percentages of patients with BP < 140/90 mmHg were 73.9%, 72.3%,
64.9%, 50.0% and 35.8% in patients with CKD1 to CKD5 stages, respectively.
But when the patients were discharged, these percentages were 78.3%,
76.9%, 70.1%, 46.7% and 39.9% in patients with CKD1 to CKD5 stages,
respectively.
S110 Chronic Kidney DiseaseConclusion: The prevalence of hypertension in our inpatients was very
high. Most of the patients with hypertension were treated by two or
more types of antihypertensive drugs. The most frequently used antihyper-
tensive drug was CCB. Less than half of the patients used RASI to treat hy-
pertension and the control of hypertension was poor. But we improved the
situation of SBP and the up-to-standard rate of blood pressure by
hospitalization.http://dx.doi.org/10.1016/j.hkjn.2015.09.155
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Objective: To assess the efficacy and safety of dipeptidyl peptidase-4
(DPP-4) inhibitors compared with placebo or with other hypoglycaemic
drugs in patients with type 2 diabetes mellitus and severe renal impair-
ment (RI).
Methods: A meta-analysis of RCTs was performed in adults with type 2 dia-
betes mellitus and severe RI, and assessed the comparative effect of DPP-4
inhibitors on HbA1C and fasting blood glucose (FPG). Safety was evaluated
based on analysis of percentage of hypoglycemia, occurrence of any adverse
events (AE) and any serious adverse events (SAE), the incidence of periph-
eral edema, urinary tract infection, diarrhea and death.
Results: Five RCTs and 503 patients were included. Compared with placebo
or no treatment, DPP-4 inhibitors were associated with a larger decline in
HbA1c (MD 0.57; 95% CI 0.73 to 0.41; P < 0.01) but not with FPG (MD
0.26; 95% CI 1.40 to 0.8; P Z 0.66). Compared with glipizide monother-
apy, no significant difference reached in HbA1c (MD 0.15; 95% CI 0.19 to
0.49; PZ 0.38) and FPG (MD 0.26; 95% CI 1.16 to 0.64; PZ 0.57). Similar
odds of any or serious adverse events between DPP-4 inhibitors and
comparators.
Conclusion: In type 2 diabetes mellitus and severe RI, treatment with DPP-4
inhibitors is safe and can effectively low HbA1c.http://dx.doi.org/10.1016/j.hkjn.2015.09.156
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Table 1 Multivariate analysis of different levels of eGFR associated with all
Baseline lev
 90
HR (95% Cl) p-value HR (95 %Cl)
Unadjusted Ref. 1.256 (1.156-1
Adjusted
Model 1 Ref. 0.959 (0.876-1
Model 2 Ref. 1.005 (0.916-1
Model 3 Ref. 1.051 (0.954-1
Model 4 Ref. 1.062 (0.946-1
Model 1: Adjusted for age, sex.
Model 2: Model 1+ BMI, HP, CVD, DM, smoking, drinking.
Model 3: Model 2 + ALB, ALT, AST, TG, GLU, hemoglobin, CRP.
Model 4: Model 3 + treatment (chemotherapy, surgery, combined treatment, b5Institute of Public Health, National Yang-Ming University, Kaohsiung,
Taiwan
Objective: Atrial fibrillation (AF) increases risk of thromboembolism events
and is prevalent among chronic kidney disease (CKD) patients. However, the
impact of AF on the mortality, acute coronary syndrome (ACS), and renal
function decline in CKD population are rare investigated. We determined
the association between incident AF and risk of death, cardiovascular
events, and end-stage renal disease (ESRD) among adults with CKD using na-
tional health insurance database in Taiwan.
Methods: CKD patients enrolled in the Pre-end stage renal disease (Pre-ESRD)
care management program,  18 years patients who were at least one outpa-
tient diagnosis codes (ICD-9 codes 585, 581.9) or at least one inpatient diagnosis
codes and free of any dialysis or renal transplant from Jan 1st 2007 to Dec 31st
2011 were included. CKD patients with AF were 1:5matched to control subjects
without AF by age, sex, urbanization, and socioeconomic status. Cox propor-
tional hazards regression models were used to estimate hazard ratios (HRs) for
all-cause mortality, cardiovascular events, and renal function decline analysis.
Results:Weincluded1995CKDpatientswithAF;of these,746 (37.4%)death,148
(7.4%)hadACS,222 (11.1%)had strokeor thromboembolism,and207 (10.4%)had
rapid eGFR decline. As compared with the CKD without AF subjects, those with
AFwasassociatedwithmultivariate-adjustedHRsof1.64 (95%CI, 1.49e1.81) for
death, 1.41 (95% CI, 1.14e1.74) for ACS, 2.15 (95% CI, 1.79e2.58) for stroke or
thromboembolism, 1.50 (95% CI, 1.31e1.73) for ESRD, and 3.35 (95% CI,
2.80e4.00) for rapid eGFR decline after adjusting comorbid disorders, clinical
characteristics, medications, and competing risk of mortality.
Conclusion: AF is independently associated with increased risk of developing
ACS, thromboembolism, and progression to ESRD in adults with CKD.http://dx.doi.org/10.1016/j.hkjn.2015.09.157
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Prevalence and Effect of Renal Insufficiency in Newly Diagnosed Solid
Cancer Patients: A Large Cohort Study with 9128 Patients from China
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Objective: To estimate the prevalence and the effect of abnormal renal
function in newly solid cancer patients.
Methods: From January 1, 2010 to December 31, 2010, 9128 patients with
newly diagnosed solid cancer in a cancer center were retrospectively stud-
ied. Renal function was calculated for each patients using Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula at the time of diag-
nosis. The prevalence of renal insufficiency (RI) and effect of RI on mortality
according to different treatments in these patients were investigated.
Results: Of the total 9128 patients, 31.7% had RI (eGFR < 90 ml/min/
1.73 m2), 2.9% had CKD (eGFR < 60 ml/min/1.73 m2), and 0.2% had
eGFR < 30 ml/min/1.73 m2. Patients with lymphoma and lung cancer have
the highest prevalence of CKD (4.3%, 4.1% respectively). Of the total pa-
tients, the number of patients who received treatment of surgery, chemo-
therapy, combination of surgery and chemotherapy, and best support care
(BSC) was 3131, 3110, 2035, 852, respectively. After multivariate analysis,
eGFR < 60 ml/min/1.73 m2 was found to be an independent risk factor for-cause mortality.
els of eGFR (ml/min/1.73m2)
60e89 <60
p-value HR (95% Cl) p-value
.365) <0.001 1.969 (1.630-2.379) <0 001
.049) 0.364 1.361 (1.121-1.653) 0.002
.103) 0.917 1.413 (1.155-1.729) 0.001
.158) 0.314 1.259 (1.021-1.553) 0.031
.171) 0.222 1.272 (1.031-1.570) 0.025
est supportive care).
